Cytokinetics Inc CYTK:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$50.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$47.54 (3)
Ask (Size)$52.50 (49)
Day Low / HighN/A - N/A
Volume850.6 K
Sell
Buy

Cytokinetics Says FDA Advisory Committee to Meet in December to Review NDA for Heart Disease Drug

8:08AM ET 6/24/2022 MT Newswires
Cytokinetics (CYTK) said Friday the US Food and Drug Administration's cardiovascular and renal drugs advisory committee will meet on Dec. 13 to review its new drug application for heart disease drug candidate omecamtiv mecarbil.

The drugmaker said the FDA set the Prescription Drug User Fee Act target action date on Feb. 28, 2023.

Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction.

Cytokinetics shares were down 0.2% in recent premarket trading Friday.

Price: 47.37, Change: -0.1, Percent Change: -0.21

Most Popular Keyword Searches

NFLX GE amd F ddd spy BABA AAPL TWTR bac FB amzn JCP tsla znga FNMA MSFT GPRO Enter Symbol or Name MJNA